Cargando…
Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience
OBJECTIVES: The treatments of limbic and other autoimmune encephalitis include immunosuppression, symptomatic treatment, and in the case of paraneoplastic syndromes, appropriate therapy for underlying neoplasms. When immunotherapy is considered, intravenous immunoglobulin is one option for treatment...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122256/ https://www.ncbi.nlm.nih.gov/pubmed/30202534 http://dx.doi.org/10.1177/2054270418793021 |
_version_ | 1783352617290694656 |
---|---|
author | Kinsella, JA Irani, SR Hollingsworth, R O’Shaughnessy, D Kane, P Foster, M Schott, JM Lunn, MP |
author_facet | Kinsella, JA Irani, SR Hollingsworth, R O’Shaughnessy, D Kane, P Foster, M Schott, JM Lunn, MP |
author_sort | Kinsella, JA |
collection | PubMed |
description | OBJECTIVES: The treatments of limbic and other autoimmune encephalitis include immunosuppression, symptomatic treatment, and in the case of paraneoplastic syndromes, appropriate therapy for underlying neoplasms. When immunotherapy is considered, intravenous immunoglobulin is one option for treatment, either alone or in combination with corticosteroids. To date, however, evidence for the use of intravenous immunoglobulin in this context comes from case series/expert reviews as no controlled trials have been performed. We aimed to analyse the NHS England Database of intravenous immunoglobulin usage, which was designed to log use and guide procurement, to explore usage and therapeutic effect of intravenous immunoglobulin in autoimmune encephalitis in England. DESIGN: We conducted a retrospective audit and review of the NHS England Database on intravenous immunoglobulin use. SETTING: NHS England Database of intravenous immunoglobulin use which covers secondary and tertiary care prescribing and use of intravenous immunoglobulin for all patients in hospitals in England. PARTICIPANTS: Hospital in-patients with confirmed or suspected autoimmune/limbic encephalitis between September 2010 and January 2017. RESULTS: A total of 625 patients who were 18 years of age or older were treated with intravenous immunoglobulin for autoimmune encephalitis, of whom 398 were determined as having 'highly likely' or 'definite' autoimmune/limbic encephalitis. Ninety-six percent were treated with a single course of intravenous immunoglobulin. The availability and accuracy of reporting of outcomes was very poor, with complete data only available in 27% of all cases. CONCLUSIONS: This is the first review of data from this unique national database. Whilst there was evidence for clinical improvement in many cases of patients treated with intravenous immunoglobulin, the quality of outcome data was generally inadequate. Methods to improve quality, accuracy and completeness of reporting are crucial to maximise the potential value of this resource as an auditing tool. |
format | Online Article Text |
id | pubmed-6122256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-61222562018-09-10 Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience Kinsella, JA Irani, SR Hollingsworth, R O’Shaughnessy, D Kane, P Foster, M Schott, JM Lunn, MP JRSM Open Research OBJECTIVES: The treatments of limbic and other autoimmune encephalitis include immunosuppression, symptomatic treatment, and in the case of paraneoplastic syndromes, appropriate therapy for underlying neoplasms. When immunotherapy is considered, intravenous immunoglobulin is one option for treatment, either alone or in combination with corticosteroids. To date, however, evidence for the use of intravenous immunoglobulin in this context comes from case series/expert reviews as no controlled trials have been performed. We aimed to analyse the NHS England Database of intravenous immunoglobulin usage, which was designed to log use and guide procurement, to explore usage and therapeutic effect of intravenous immunoglobulin in autoimmune encephalitis in England. DESIGN: We conducted a retrospective audit and review of the NHS England Database on intravenous immunoglobulin use. SETTING: NHS England Database of intravenous immunoglobulin use which covers secondary and tertiary care prescribing and use of intravenous immunoglobulin for all patients in hospitals in England. PARTICIPANTS: Hospital in-patients with confirmed or suspected autoimmune/limbic encephalitis between September 2010 and January 2017. RESULTS: A total of 625 patients who were 18 years of age or older were treated with intravenous immunoglobulin for autoimmune encephalitis, of whom 398 were determined as having 'highly likely' or 'definite' autoimmune/limbic encephalitis. Ninety-six percent were treated with a single course of intravenous immunoglobulin. The availability and accuracy of reporting of outcomes was very poor, with complete data only available in 27% of all cases. CONCLUSIONS: This is the first review of data from this unique national database. Whilst there was evidence for clinical improvement in many cases of patients treated with intravenous immunoglobulin, the quality of outcome data was generally inadequate. Methods to improve quality, accuracy and completeness of reporting are crucial to maximise the potential value of this resource as an auditing tool. SAGE Publications 2018-09-03 /pmc/articles/PMC6122256/ /pubmed/30202534 http://dx.doi.org/10.1177/2054270418793021 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Kinsella, JA Irani, SR Hollingsworth, R O’Shaughnessy, D Kane, P Foster, M Schott, JM Lunn, MP Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience |
title | Use of intravenous immunoglobulin for the treatment of autoimmune
encephalitis: audit of the NHS experience |
title_full | Use of intravenous immunoglobulin for the treatment of autoimmune
encephalitis: audit of the NHS experience |
title_fullStr | Use of intravenous immunoglobulin for the treatment of autoimmune
encephalitis: audit of the NHS experience |
title_full_unstemmed | Use of intravenous immunoglobulin for the treatment of autoimmune
encephalitis: audit of the NHS experience |
title_short | Use of intravenous immunoglobulin for the treatment of autoimmune
encephalitis: audit of the NHS experience |
title_sort | use of intravenous immunoglobulin for the treatment of autoimmune
encephalitis: audit of the nhs experience |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122256/ https://www.ncbi.nlm.nih.gov/pubmed/30202534 http://dx.doi.org/10.1177/2054270418793021 |
work_keys_str_mv | AT kinsellaja useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience AT iranisr useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience AT hollingsworthr useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience AT oshaughnessyd useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience AT kanep useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience AT fosterm useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience AT schottjm useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience AT lunnmp useofintravenousimmunoglobulinforthetreatmentofautoimmuneencephalitisauditofthenhsexperience |